Azopharma, ABP Enter Tablet Tech Pact

Azopharma Product Development Group, Inc. and Accu-Break Pharmaceuticals, Inc. (ABP) have signed a strategic alliance agreement in which Azopharma will develop products based on ABP’s Accu-Break tablet technologies. The agreement spans five years and Azopharma Product Development Group will also provide sales and marketing support.
   
Dr. Allan Kaplan, chief executive officer of ABP stated, “ABP’s patented Accu-Break technologies create an inactive break layer in tablets, allowing them to be broken into accurate partial doses. By breaking at the inactive layer, accurate dose splitting can be guaranteed, since the active layer remains undisturbed. The Accu-Break technologies have important implications for pharmaceutical companies as well as physicians and their patients.”
   
Phil Meeks, chief executive officer of Azopharma, commented, “These new patented technologies will help pharmaceutical companies in many ways. From creating new products utilizing these novel technologies to gaining competitive market share by modifying existing products, we expect the pharmaceutical companies to be greatly affected by the Accu-Break technologies.”